Mankind Pharma Limited

NSE: MANKIND · Healthcare · Lot size: 225

OverviewOption ChainOI AnalysisFII / DIIMax Pain

Mankind Pharma Limited Share Price & Analysis

₹2,531.4Updated 22 Jul 2026, 03:30 pm IST
LTP
₹2,531.4
—
Open
₹2,564.1
High
₹2,566.8
Low
₹2,513
Close
₹2,579.5
52W High
₹2,707
52W Low
₹1,910
Volume
294K
Lot Size
225
Sector
Healthcare
Market Cap
₹1.0L Cr
Face Value
₹1
Large CapNIFTY 200NIFTY 500MIDCAP 100

Price Chart

Fundamentals

P/E
51
Sector P/E
54.4
P/B
6.41
EPS
₹43.11
ROE
13.1%
ROCE
13.5%
D/E Ratio
0.39
Div Yield
0.04%
Book Value
₹395
+

Strengths

  • ✓Low debt relative to equity (D/E 0.4x)

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
₹1,944
₹4.6L Cr37.35.591620.50.07
DIVISLAB
Divi's Laboratories Limited
₹7,388
₹1.9L Cr73.411.7116.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
₹5,040
₹1.6L Cr73.620.3227.415.20.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
₹8,939
₹1.3L Cr64.913.5622.117.90.88
CIPLA
Cipla Limited
₹1,416
₹1.1L Cr30.13.3211.615.50.01
ZYDUSLIFE
Zydus Lifesciences Limited
₹1,123
₹1.1L Cr214.1721.221.10.38
LUPIN
Lupin Limited
₹2,405
₹1.1L Cr19.64.928.729.90.32

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

MANKIND · as of Mar 2026

Promoters72.70%
FII12.92%▼0.42
DII11.47%▲0.42
Public2.89%
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters76.50%74.88%74.87%74.87%72.71%72.70%
FII6.74%9.87%11.58%12.37%13.34%12.92%
DII9.78%11.14%9.94%9.91%11.05%11.47%
Public6.97%4.10%3.61%2.86%2.89%2.89%

Corporate Events

To consider and approve the financial results for the period ended Jun 30, 2026

Results29 Jul 2026

To consider and approve the financial results for the period ended March 31, 2026

Results18 May 2026

Interim Dividend - Re 1 Per Share

Dividend7 Aug 2025

Latest News

All news →

Mankind Pharma shares to face block trading

Mankind Pharma has published a newspaper notice regarding a block deal. The transaction involves a portion of promoter-held shares. No financial details disclosed, likely routine stake restructuring. 📊 *STOCKS:* MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #blockdeal

NSE Filing10 Jul
Low Impact

Mankind Pharma shares may see volatility on newspaper publication

*Mankind Pharma shares may see volatility on newspaper publication.* The company filed a copy of a newspaper publication with the NSE, likely related to a regulatory or corporate disclosure. Such filings are routine and typically do not carry material business implications. Impact on trading is expected to be minimal. 📊 *STOCKS:* MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma

NSE Filing1 Jul
Low Impact

Mankind Pharma announces general corporate updates

*Mankind Pharma announces general corporate updates.* No specific financial or operational details disclosed. The filing does not reveal any major strategic moves or results. Traders may await further clarity. 📊 *STOCKS:* MANKIND | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporateupdate

NSE Filing30 Jun
Low Impact

Financials

Quarterly Results

MetricDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
Revenue
₹3.6K Cr
▼3.5%
₹3.7K Cr
▲3.6%
₹3.6K Cr
▲15.9%
₹3.1K Cr
▼3.8%
₹3.2K Cr
▲4.5%
₹3.1K Cr
▲6.7%
₹2.9K Cr
▲18.4%
₹2.4K Cr
Op. Profit
₹919 Cr
▼0.2%
₹921 Cr
▲8.7%
₹847 Cr
▲24.0%
₹683 Cr
▼16.3%
₹816 Cr
▼3.7%
₹847 Cr
▲26.0%
₹672 Cr
▲14.7%
₹586 Cr
OPM
26.0%
▲4.0%
25.0%
▲4.2%
24.0%
▲9.1%
22.0%
▼15.4%
26.0%
▼7.1%
28.0%
▲21.7%
23.0%
▼4.2%
24.0%
Net Profit
₹414 Cr
▼20.4%
₹520 Cr
▲16.9%
₹445 Cr
▲4.7%
₹425 Cr
▲10.4%
₹385 Cr
▼41.6%
₹659 Cr
▲21.4%
₹543 Cr
▲13.8%
₹477 Cr
EPS (₹)
9.9
▼20.1%
12.39
▲16.7%
10.62
▲4.1%
10.2
▲10.6%
9.22
▼43.5%
16.31
▲21.8%
13.39
▲13.9%
11.76

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2015
Revenue
₹14.3K Cr
▲17.0%
₹12.2K Cr
▲19.0%
₹10.3K Cr
▲17.3%
₹8.7K Cr
▲12.4%
₹7.8K Cr
▲25.2%
₹6.2K Cr
▲6.0%
₹5.9K Cr
▲75.9%
₹3.3K Cr
Expenses
₹10.7K Cr
▲16.0%
₹9.2K Cr
▲18.6%
₹7.7K Cr
▲13.1%
₹6.8K Cr
▲18.3%
₹5.8K Cr
▲26.9%
₹4.6K Cr
▲3.1%
₹4.4K Cr
▲61.1%
₹2.7K Cr
Op. Profit
₹3.6K Cr
▲19.8%
₹3.0K Cr
▲20.2%
₹2.5K Cr
▲32.3%
₹1.9K Cr
▼4.5%
₹2.0K Cr
▲20.7%
₹1.6K Cr
▲14.7%
₹1.4K Cr
▲145.4%
₹586 Cr
OPM
25.0%
▲0.0%
25.0%
▲0.0%
25.0%
▲13.6%
22.0%
▼15.4%
26.0%
▼3.7%
27.0%
▲8.0%
25.0%
▲38.9%
18.0%
Other Income
₹238 Cr
▼56.6%
₹548 Cr
▲85.8%
₹295 Cr
▲109.2%
₹141 Cr
▼32.9%
₹210 Cr
▲14.8%
₹183 Cr
▲50.0%
₹122 Cr
▲60.5%
₹76 Cr
Interest
₹644 Cr
▲49.1%
₹432 Cr
▲1170.6%
₹34 Cr
▼26.1%
₹46 Cr
▼23.3%
₹60 Cr
▲185.7%
₹21 Cr
▼8.7%
₹23 Cr
▲1050.0%
₹2 Cr
Depreciation
₹886 Cr
▲42.7%
₹621 Cr
▲64.3%
₹378 Cr
▲16.0%
₹326 Cr
▲95.2%
₹167 Cr
▲40.3%
₹119 Cr
▲20.2%
₹99 Cr
▲153.8%
₹39 Cr
PBT
₹2.3K Cr
▼7.5%
₹2.5K Cr
▲5.1%
₹2.4K Cr
▲43.6%
₹1.7K Cr
▼15.4%
₹2.0K Cr
▲16.7%
₹1.7K Cr
▲17.7%
₹1.4K Cr
▲131.6%
₹621 Cr
Tax %
17.0%
▼15.0%
20.0%
▲5.3%
19.0%
▼13.6%
22.0%
▼15.4%
26.0%
▲8.3%
24.0%
▼11.1%
27.0%
▼6.9%
29.0%
Net Profit
₹1.9K Cr
▼3.6%
₹2.0K Cr
▲3.6%
₹1.9K Cr
▲48.2%
₹1.3K Cr
▼9.8%
₹1.5K Cr
▲12.4%
₹1.3K Cr
▲22.4%
₹1.1K Cr
▲137.3%
₹445 Cr
EPS (₹)
46.34
▼4.0%
48.26
▲1.1%
47.75
▲49.2%
32
▼10.6%
35.78
▲13.3%
31.59
▲22.8%
25.72
▼88.3%
219.33
Div Payout
2.0%
0.0%
0.0%
0.0%
0.0%
▼100.0%
24.0%
0.0%
0.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemMar 2026Sep 2025Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2015
Liabilities
Equity Capital
₹41 Cr
▲0.0%
₹41 Cr
▲0.0%
₹41 Cr
▲2.5%
₹40 Cr
▲0.0%
₹40 Cr
▲0.0%
₹40 Cr
▲0.0%
₹40 Cr
▲0.0%
₹40 Cr
▲100.0%
₹20 Cr
Reserves
₹16.3K Cr
▲6.7%
₹15.2K Cr
▲6.7%
₹14.3K Cr
▲53.3%
₹9.3K Cr
▲26.1%
₹7.4K Cr
▲20.9%
₹6.1K Cr
▲30.6%
₹4.7K Cr
▲35.9%
₹3.4K Cr
▲69.3%
₹2.0K Cr
Borrowings
₹6.3K Cr
▼24.6%
₹8.4K Cr
▼1.7%
₹8.5K Cr
▲4011.6%
₹207 Cr
▲21.8%
₹170 Cr
▼80.5%
₹873 Cr
▲262.2%
₹241 Cr
▲84.0%
₹131 Cr
₹0 Cr
Other Liabilities
₹5.1K Cr
▼0.3%
₹5.2K Cr
▲7.3%
₹4.8K Cr
▲107.9%
₹2.3K Cr
▲11.2%
₹2.1K Cr
▲0.0%
₹2.1K Cr
▲48.9%
₹1.4K Cr
▼3.6%
₹1.4K Cr
▲49.7%
₹968 Cr
Total Liabilities
₹27.8K Cr
▼3.7%
₹28.8K Cr
▲4.2%
₹27.7K Cr
▲132.7%
₹11.9K Cr
▲22.7%
₹9.7K Cr
▲6.3%
₹9.1K Cr
▲43.2%
₹6.4K Cr
▲25.6%
₹5.1K Cr
▲67.6%
₹3.0K Cr
Assets
Fixed Assets
₹18.6K Cr
▼3.3%
₹19.3K Cr
▲1.4%
₹19.0K Cr
▲318.2%
₹4.5K Cr
▲6.9%
₹4.3K Cr
▲18.5%
₹3.6K Cr
▲115.6%
₹1.7K Cr
▲4.0%
₹1.6K Cr
▲406.3%
₹316 Cr
CWIP
₹1.1K Cr
▲186.3%
₹394 Cr
▼52.3%
₹826 Cr
▲192.9%
₹282 Cr
▼48.7%
₹550 Cr
▼21.5%
₹701 Cr
▲88.4%
₹372 Cr
▲17.4%
₹317 Cr
▲574.5%
₹47 Cr
Investments
₹2.0K Cr
▼32.6%
₹2.9K Cr
▲44.3%
₹2.0K Cr
▼20.5%
₹2.6K Cr
▲90.8%
₹1.3K Cr
▲21.4%
₹1.1K Cr
▼26.7%
₹1.5K Cr
▲82.4%
₹829 Cr
▼13.6%
₹959 Cr
Other Assets
₹6.0K Cr
▼3.0%
₹6.2K Cr
▲7.4%
₹5.8K Cr
▲28.8%
₹4.5K Cr
▲26.9%
₹3.5K Cr
▼4.6%
₹3.7K Cr
▲31.9%
₹2.8K Cr
▲21.2%
₹2.3K Cr
▲36.4%
₹1.7K Cr
Total Assets
₹27.8K Cr
▼3.7%
₹28.8K Cr
▲4.2%
₹27.7K Cr
▲132.7%
₹11.9K Cr
▲22.7%
₹9.7K Cr
▲6.3%
₹9.1K Cr
▲43.2%
₹6.4K Cr
▲25.6%
₹5.1K Cr
▲67.6%
₹3.0K Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2015
Operating CF
₹3.1K Cr
▲29.3%
₹2.4K Cr
▲12.1%
₹2.2K Cr
▲18.7%
₹1.8K Cr
▲97.1%
₹920 Cr
▼19.1%
₹1.1K Cr
▲6.3%
₹1.1K Cr
—
Investing CF
₹-181 Cr
▲98.6%
₹-12.6K Cr
▼506.6%
₹-2.1K Cr
▼97.8%
₹-1.1K Cr
▲23.2%
₹-1.4K Cr
▼12.0%
₹-1.2K Cr
▼180.3%
₹-436 Cr
—
Financing CF
₹-3.0K Cr
▼128.9%
₹10.2K Cr
▲204560.0%
₹5 Cr
▲100.7%
₹-740 Cr
▼222.3%
₹605 Cr
▲7662.5%
₹-8 Cr
▲98.5%
₹-531 Cr
—
Net Cash Flow
₹-12 Cr
▼154.5%
₹22 Cr
▼71.4%
₹77 Cr
▲250.0%
₹22 Cr
▼85.9%
₹156 Cr
▲269.6%
₹-92 Cr
▼189.3%
₹103 Cr
—
Free Cash Flow
₹2.4K Cr
▲26.0%
₹1.9K Cr
▲7.0%
₹1.8K Cr
▲79.4%
₹987 Cr
▲169.4%
₹-1.4K Cr
▼272.3%
₹826 Cr
▼3.2%
₹853 Cr
—

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2015
Debtor Days
44d
▼4.3%
46d
▲53.3%
30d
▲25.0%
24d
▲33.3%
18d
▼5.3%
19d
▼42.4%
33d
▲50.0%
22d
Inventory Days
193d
▼11.9%
219d
▲21.7%
180d
▼4.3%
188d
▼29.1%
265d
▲9.1%
243d
▲38.9%
175d
▲5.4%
166d
Days Payable
121d
▲1.7%
119d
▲32.2%
90d
▼28.6%
126d
▼22.2%
162d
▲18.2%
137d
▼5.5%
145d
▲104.2%
71d
Cash Conv. Cycle
117d
▼19.9%
146d
▲21.7%
120d
▲39.5%
86d
▼28.9%
121d
▼3.2%
125d
▲98.4%
63d
▼46.2%
117d
Working Capital Days
-40d
▼42.9%
-28d
▼152.8%
53d
▲35.9%
39d
▲62.5%
24d
▼25.0%
32d
▲6.7%
30d
▼46.4%
56d
ROCE
14.0%
▼17.6%
17.0%
▼34.6%
26.0%
▲18.2%
22.0%
▼31.3%
32.0%
▼13.5%
37.0%
—
—

Source: Screener.in · Lower days = better efficiency

Deep Dive Analysis

Option Chain
Strike-wise OI & IV
OI Analysis
PCR, buildup type
FII / DII
Institutional flows
Max Pain
Writer pain levels

About Mankind Pharma Limited

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

Healthcare · Pharmaceuticals & Biotechnology

Related Analysis

Same Sector

ALKEM
Alkem Laboratories Limited
Neutral
APOLLOHOSP
Apollo Hospitals Enterprise Limited
Neutral
AUROPHARMA
Aurobindo Pharma Limited
Neutral
BIOCON
Biocon Limited
Neutral
CIPLA
Cipla Limited
Neutral

Frequently Asked Questions

What is Mankind Pharma Limited share price today?▾
Mankind Pharma Limited (MANKIND) is currently trading at ₹2,531.4 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Mankind Pharma Limited available in F&O (Futures & Options)?▾
Yes, Mankind Pharma Limited (MANKIND) is part of the NSE F&O segment with a lot size of 225 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Mankind Pharma Limited 52-week high and low?▾
Mankind Pharma Limited's 52-week high is ₹2,707 and the 52-week low is ₹1,910. The current price of ₹2,531.4 is 6.5% below the 52W high.
What is Mankind Pharma Limited P/E ratio?▾
Mankind Pharma Limited's current P/E ratio is 51. This indicates the market is paying ₹51 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Mankind Pharma Limited options?▾
Mankind Pharma Limited options are traded on NSE with monthly expiry contracts (lot size: 225 shares). To trade MANKIND options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.